AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.
Saved in:
| Title: | AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. |
|---|---|
| Authors: | Zabludoff SD; AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA. sonya.zabludoff@astrazeneca.com, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL, Green S, Haye HR, Horn CL, Janetka JW, Liu D, Mouchet E, Ready S, Rosenthal JL, Queva C, Schwartz GK, Taylor KJ, Tse AN, Walker GE, White AM |
| Source: | Molecular cancer therapeutics [Mol Cancer Ther] 2008 Sep; Vol. 7 (9), pp. 2955-66. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print Cited Medium: Print ISSN: 1535-7163 (Print) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
